The FDA has authorized ZYN nicotine pouches to be marketed as a less harmful alternative to cigarettes, but quitting all tobacco remains the best choice.
New Delhi, India Jul 3, 2026 ALN: On June 30, the US Food and Drug Administration (FDA) authorized 20 ZYN nicotine pouch products to carry a specific “modified risk” claim. This means that in the US, ZYN can now assert that “using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.” This decision marks a significant moment in the ongoing dialogue about tobacco alternatives and public health, especially as the landscape of nicotine consumption continues to evolve.
The FDA's ruling does not imply that nicotine pouches are safe or approved as smoking cessation products. Instead, it allows Swedish Match, the manufacturer of ZYN, to market certain products as a less harmful alternative for adults who completely switch away from cigarettes. This distinction is crucial as it emphasizes that while the products may present lower risks compared to traditional cigarettes, they are not devoid of health concerns.
The regulatory green light comes at a time when the nicotine-pouch boom has already reshaped the conversation about alternatives to smoking. Nicotine pouches have become one of the fastest-growing nicotine categories globally, fueled by their discreet nature, lack of smoke or vapor, and growing perceptions that they represent a “cleaner” form of nicotine consumption. The appeal of these products lies in their convenience and the perception that they are less harmful than traditional smoking methods.
According to a recent report by the World Health Organization (WHO), global retail sales of nicotine pouches reached 23.4 billion units in 2024, an increase of more than 50 percent from the previous year, underscoring just how quickly the category is growing. This surge in popularity highlights a significant shift in consumer behavior, with many individuals seeking alternatives to traditional tobacco products.
The FDA announcement comes as the WHO warns that nicotine pouches are spreading so rapidly that regulation is struggling to keep pace in many countries. The WHO has raised concerns that brands are increasingly using social media, influencers, and youth-oriented marketing to promote them. This trend raises alarms about the potential for increased nicotine addiction among younger demographics who may be drawn to these products.
It’s the first time regulators have formally endorsed an idea that many younger nicotine users had already embraced. It is not, however, a blessing for the category; in many ways, regulators are simply catching up with a cultural shift that already happened. The rapid growth of nicotine pouches reflects changing attitudes toward smoking and nicotine consumption, particularly among younger individuals who may be more inclined to experiment with alternatives to traditional tobacco.
The market for smoking alternatives has splintered well beyond the offerings of a decade ago. While nicotine-replacement therapies such as patches, gum, and inhalers remain FDA-approved tools designed to help people quit smoking, they now compete with a rapidly expanding ecosystem of alternative nicotine products. This diversification reflects a broader trend in public health, where individuals are increasingly seeking options that align with their lifestyles and preferences.
Oral nicotine pouches have rapidly become one of the biggest growth categories within this market. ZYN and other brands like On! and VELO have become the front-runners in the oral nicotine market globally. Their rise can be attributed to a combination of factors, including effective marketing strategies, product innovation, and a growing consumer base that values convenience and discretion.
Vapes and disposable e-cigarettes, meanwhile, still take the biggest share of the global smoking-alternative category, projected to hit $14.8 billion by 2030 in the US, even though they’re still dogged by headlines about youth use. Heated tobacco devices, like IQOS, offer another choice by heating tobacco instead of burning it, which lowers exposure to many of the harmful chemicals found in cigarette smoke. Each of these alternatives presents its own set of risks and benefits, complicating the landscape for consumers and regulators alike.
Public health officials remain cautious about nicotine pouches. The WHO has warned that they are becoming increasingly popular among adolescents and young adults because of their “strong youth appeal and high addiction potential,” raising concerns that products initially marketed to smokers could also attract new users. This concern is particularly relevant in the context of rising nicotine addiction rates among youth, which have become a significant public health issue.
Based on toxicology data, consumer research, and public health modeling, the FDA granted a Modified Risk Tobacco Product (MRTP) order to 10 ZYN flavors at each of two strengths—3 milligrams and 6 milligrams. This allows Swedish Match to market those specific products as a lower-risk alternative for adults who switch completely away from cigarettes. The FDA's decision is based on the premise that providing smokers with information about lower-risk alternatives can empower them to make healthier choices.
The new designations are a big win for the tobacco industry, but there are two significant caveats. First, the ruling only applies to 20 specific products, not all nicotine pouches. This means that while some products may be marketed as lower risk, others may not have undergone the same level of scrutiny or evaluation. Second, the FDA’s findings only apply to smokers who fully switch to these pouches. Those who use cigarettes or vapes in addition to pouches won’t receive the same benefit, highlighting the importance of complete cessation for health improvement.
The FDA has advised non-tobacco users against using nicotine pouches. “FDA’s review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices,” said Bret Koplow, acting director of the FDA’s Center for Tobacco Products. He also stated that the decision “informs adults who smoke about the lower risks associated with these products.” This emphasis on informed decision-making is critical in a landscape where misinformation can easily spread.
Swedish Match must also keep track of real-world usage and report back to the FDA. The MRTP order is valid for five years, unless it is renewed or withdrawn. This ongoing oversight reflects a commitment to monitoring the impact of these products on public health and ensuring that they are used as intended.
The FDA’s message is relatively straightforward: Adults who smoke and completely switch to certain nicotine pouches are likely reducing their health risks compared to continuing to smoke cigarettes. However, the agency also stresses that there is no safe tobacco product and that fully quitting all tobacco and nicotine products remains the best option for better health. This dual messaging underscores the complexity of tobacco regulation and the need for continuous public health education.
Who ultimately uses nicotine pouches—and whether their rapid growth creates a new generation of nicotine users—is a separate question entirely. As the market for these products continues to expand, it will be essential for public health officials, educators, and policymakers to monitor trends in usage and address potential health implications, particularly among vulnerable populations. The long-term effects of nicotine pouch use, especially among young people, remain to be seen, and ongoing research will be necessary to fully understand the consequences of this evolving landscape.
To learn more about the latest developments in Healthcare Innovations, stay updated with our exclusive reports and analyses on AiLensNews.
